|
|
|
Personalized
Medicine Programs |
| |
Perlegen
Expands Leadership Team to Prepare For Landmark Personalized
Medicine Programs
Other topics: Telemedicine
Equipment, Medical
Informatics Cancer Treatments,
Personalized Medicine Programs
BUSINESS WIRE
October 31, 2007
MOUNTAIN VIEW, California - Perlegen Sciences announced today
the successful recruitment of three senior professionals to help
the company prepare for several key landmark drug response
studies. Patient identification and DNA collection is already
underway for the initial study, with additional sample
collections scheduled to commence before year end. |
| |
|
|
| |
A leader in
discovering and understanding the role that human genetic
variation plays in patients' response to drugs, Perlegen applies
next generation re-sequencing and SNP genotyping across the
genomes of thousands of patients to determine those variations
associated with given traits of interest. This approach also has
utility in identifying patients predisposed to various diseases,
as evidenced by the company's recently published findings
related to breast cancer and myocardial infarction.
Joining the company's senior operations team are Ellen M.
Beasley, Ph.D., Keith Joho, Ph.D. and Jeff Otto, Ph.D. "With the
addition of these key executives, Perlegen's operating team has
transitioned to a fully matrixed organization, quickly and
efficiently delivering genotype information, production
sequencing and genetic analyses aimed at uncovering the
important genetic drivers behind variable drug response in a
variety of key clinical situations," commented Perlegen CEO
Bryan Walser, M.D. "It is a pleasure to welcome Ellen, Keith and
Jeff, each of whom shares our vision and urgency to make a real
difference in patient treatments."
Dr. Beasley joins Perlegen as Vice President of Project
Management, prior to which she held a number of leadership roles
with Celera Group including Senior Director of Therapeutics
Alliances, Senior Director of Bioinformatics and Director of
Gene Discovery. Prior to Celera, she was a project manager at
the Stanford Human Genome Center. Dr. Beasley obtained a B.S.
from Trinity College in Hartford, Connecticut and a Ph.D. from
the University of Chicago prior to completing postdoctoral
training at the Biocenter of the University of Basel
(Switzerland) and Stanford University.
Dr. Joho joins Perlegen as Chief Information Officer, prior to
which he served as Senior Vice President of Research and Product
Management at Ingenuity Systems. Prior to Ingenuity, Dr. Joho
was Vice President of Informatics & Bioanalytical Operations at
SurroMed and Director of Bioinformatics at Abgenix. He has also
held positions at Roche Bioscience, SUGEN, and on the faculty of
the Department of Biochemistry and Molecular Biology at the LSU
Medical Center in New Orleans. Dr. Joho received his Ph.D. in
Microbiology at the Robert Wood Johnson Medical School.
Dr. Otto will join Perlegen in November as Vice President of
Production Operations, bringing a breadth of experience in R&D
and biotechnology operational management. He has held leadership
roles at Genaissance Pharmaceuticals, responsible for that
company's genotyping services business, and most recently at
Sequenom, Inc. where he was recruited in 2005 to start up that
company's services business. Dr. Otto received his Ph.D. in
Biology at Marquette University and his MBA at the New York
Institute of Technology.
About Perlegen Sciences
Perlegen's mission is to discover and commercialize genetic
variations that can make a difference to patients and
physicians. The company's expertise is in understanding human
genetic variation within and across diverse patient populations
and in conducting studies aimed at identifying those variations
that are predictive of drug response, both toxicity and
efficacy. For more information about the company and its
technologies, visit Perlegen's website at www.perlegen.com.
|
| |
|
|
| |
|
|
